PTC Therapeutics, Inc.

NASDAQ:PTCT

Biotechnology

Healthcare
$60.23 +0.76%

+$0.60 today

Market cap
$5.03B
Beta
0.55
P/E (TTM)
-35.0
EPS (TTM)
-$2.26
52W Low $43.18High $87.50

Volume 0.64M

Average 1.27M

PTCT Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

PTC Therapeutics, Inc.NASDAQ: PTCT

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue grows, but more slowly than its trailing trend

Q2 FY2026 cost of revenue of $19.92M rose 74.4% year over year, behind the +250.5% change in trailing-twelve-month cost of revenue. Sequentially, it fell 28.9% from the prior quarter. Over 3 fiscal years it compounded at +17.1% a year.

Context

  • Cost of revenue amounted to 4.1% of revenue in FY2025, down 3.0 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +74.4% toward the trailing-twelve-month pace of +250.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$19.92M-28.9% QoQ
Last fiscal yearDec 2025
$71.76M+25.0% YoY
LTMJun 2026
$180.19M+250.5% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+74.4%——
1 year+25.0%——
3-year CAGR+17.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
71.76M USD
Year-over-year change
+25.0%
4-year CAGR
+22.1%

Cost of Revenue vs competitors

How PTCT compares with its peers on the latest reported figures

  • PTCT's LTM Jun 2026 cost of revenue of $180.19M is the 3rd highest of the 11 companies compared; the peer median is $35.87M.
  • Its year-over-year change of +250.5% is the 3rd highest of 10, against a peer median of +91.9%.
  • Cost of revenue amounts to 17.9% of revenue for PTCT, versus a peer median of 6.7%.
PTCT Competitors Peer median
Cost of Revenue for PTCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$206.11B +35566.9%+13.6%20.1%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$821.4M +102.3%+84.7%37.6%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$180.19M +250.5%+17.1%17.9%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$109.99M +25.2%+56.7%16.4%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$47.45M +428.8%+101.9%6.7%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$42.41M -26.6%——
KRYSKrystal Biotech, Inc.LTM Jun 2026$29.34M +23.1%—6.7%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$17.04M +44.2%+4.3%1.8%
WVEWave Life Sciences Ltd.LTM Mar 2026$4.46M +106.0%—6.2%
SLDBSolid Biosciences Inc.LTM Mar 2026$781K +91.9%——
DYNDyne Therapeutics, Inc.LTM Jun 2026$521K ———
Peer median (excluding PTCT) $35.87M+91.9%+56.7%6.7%

Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue538.59M698.8M937.82M806.78M1.73B
Cost of Revenue32.33M44.68M65.49M57.4M71.76M
Gross Profit506.27M654.12M872.34M749.38M1.66B
Gross Margin94.0%93.6%93.0%92.9%95.9%
Research & Development540.68M651.5M666.56M534.48M455.25M
Selling, General & Admin285.77M326M332.54M300.91M347.14M
Operating Expenses880.71M1.1B1.31B1.05B802.39M
Depreciation & Amortization64.13M128.84M236.59M75.66M38.82M
EBITDA(368.18M)(367.78M)(330.34M)(120.46M)887.66M
EBITDA Margin-68.4%-52.6%-35.2%-14.9%51.3%
Operating Income(374.44M)(447.41M)(439.5M)(302.57M)856.51M
Operating Margin-69.5%-64.0%-46.9%-37.5%49.5%
Interest Income00000
Interest Expense86.02M90.87M129.18M166.99M152.23M
Other Income / Expenses(143.9M)(140.08M)(256.61M)(60.55M)(159.89M)
Income Before Tax(518.34M)(587.49M)(696.11M)(363.12M)696.62M
Pre-Tax Margin-96.2%-84.1%-74.2%-45.0%40.3%
Income Tax Expense5.56M(28.47M)(69.51M)176K13.98M
Net Income(523.9M)(559.02M)(626.6M)(363.3M)682.64M
Net Margin-97.3%-80.0%-66.8%-45.0%39.4%
EPS (Basic)(7.43)(7.79)(8.37)(4.73)8.58
EPS (Diluted)(7.43)(7.79)(8.37)(4.73)7.78
Weighted Avg Shares70.47M71.73M74.84M76.85M79.53M
Weighted Avg Shares (Diluted)70.47M71.73M74.84M76.85M88.31M

PTC Therapeutics, Inc.

NASDAQ:PTCT

Intrinsic Alpha fair value

Locked

Current Price

$60.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.